Mizuho initiated coverage on Axonics Modulation with a new price target
$AXNX
Medical/Dental Instruments
Health Care
Mizuho initiated coverage of Axonics Modulation with a rating of Buy and set a new price target of $75.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2024 | Outperform → Peer Perform | Wolfe Research | |
| 7/19/2023 | $69.00 | Outperform | Robert W. Baird |
| 7/13/2023 | $70.00 | Overweight | KeyBanc Capital Markets |
| 5/23/2023 | $75.00 | Buy | CL King |
| 4/14/2023 | $75.00 | Buy | Mizuho |
| 3/24/2023 | $71.00 | Hold → Buy | Needham |
| 10/21/2022 | $85.00 | Outperform | RBC Capital Mkts |
| 10/12/2022 | $75.00 | Hold | Jefferies |
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
4 - Axonics, Inc. (0001603756) (Issuer)
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str
Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20
15-12G - Axonics, Inc. (0001603756) (Filer)
EFFECT - Axonics, Inc. (0001603756) (Filer)
25-NSE - Axonics, Inc. (0001603756) (Subject)